GABAERON

Individuals carry one of three variants of the apoE gene. Carriers with the apoE4 allele have an increased risk of developing AD at an earlier age and with an increased rate of progression. GABAeron aims to treat apoE4 carriers with neurodegenerative diseases with human iPSC-derived GABAergic inhibitory interneurons to restore lost/injured hippocampal neurons as a novel first-in-class treatment... We are looking for colleagues who are team players, always learning, dedicated to conducting rigorous science, and passionate about improving the lives of patients with neurodegenerative and neurodevelopmental disorders. GABAeron has positions open for those looking to join a focused organization with opportunities to guide early lab discoveries towards meaningful disease-modifying therapeutics... We build on the promise of combining precision medicine with regenerative medicine and pharmaceutical intervention - building towards a new first-in-class IND candidate for neuron replacement in..

Primary location: San Francisco